{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:21Z","timestamp":1761101001968},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Efforts to develop curative treatment strategies for chronic lymphocytic leukemia (CLL) in recent years have focused on allogeneic stem cell transplantation (alloSCT). The crucial anti-leukemic principle of alloSCT in CLL appears to be the immune-mediated anti-host activities conferred with the graft (graft-versus-leukemia effects, GVL). Evidence for GVL in CLL is provided by studies analyzing the kinetics of minimal residual disease on response to immune modulation after transplantation, suggesting that GVL can result in complete and durable suppression of the leukemic clone. AlloSCT from matched related or unrelated donors can overcome the treatment resistance of poor-risk CLL, ie, purine analogue refractory disease and CLL with del 17p-. Even with reduced-intensity conditioning, alloSCT in CLL is associated with significant mortality and morbidity due to graft-versus-host disease, which has to be weighed against the risk of the disease when defining the indication for transplantation. Therefore, it can be regarded as a reasonable treatment option only for eligible patients who fulfill accepted criteria for poor-risk disease. If alloSCT is considered, it should be performed before CLL has advanced to a status of complete refractoriness to assure an optimum chance for a successful outcome. Prospective trials are underway to prove whether allo-SCT can indeed change the natural history of poor-risk CLL.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.602","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"602-609","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Allotransplantation for chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"2009","author":[{"given":"Peter","family":"Dreger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702061315000_R1","doi-asserted-by":"crossref","unstructured":"Tam CS, O\u2019Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975\u2013980.","DOI":"10.1182\/blood-2008-02-140582"},{"key":"2019111702061315000_R2","doi-asserted-by":"crossref","unstructured":"Hallek M, Fingerle-Rowson G, Fink A, et al. Immunochemotherapy with fludarabine, cyclophosphamide, and Rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia [abstract]. Blood. 2008;112:125.","DOI":"10.1182\/blood.V112.11.325.325"},{"key":"2019111702061315000_R3","doi-asserted-by":"crossref","unstructured":"Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood. 2006;107:1276\u20131283.","DOI":"10.1182\/blood-2005-02-0819"},{"key":"2019111702061315000_R4","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood. 2008;111:5446\u20135456.","DOI":"10.1182\/blood-2007-06-093906"},{"key":"2019111702061315000_R5","doi-asserted-by":"crossref","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278\u20133281.","DOI":"10.1182\/blood-2003-10-3729"},{"key":"2019111702061315000_R6","doi-asserted-by":"crossref","unstructured":"Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971\u20132979.","DOI":"10.1200\/JCO.2005.04.021"},{"key":"2019111702061315000_R7","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H Trial of the GCLLSG. J Clin Oncol. 2009;27:3994\u20134001.","DOI":"10.1200\/JCO.2008.21.1128"},{"key":"2019111702061315000_R8","doi-asserted-by":"crossref","unstructured":"Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291\u20135297.","DOI":"10.1182\/blood-2007-12-130120"},{"key":"2019111702061315000_R9","doi-asserted-by":"crossref","unstructured":"Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113:2637\u20132645.","DOI":"10.1182\/blood-2008-07-168583"},{"key":"2019111702061315000_R10","doi-asserted-by":"crossref","unstructured":"Michallet M, Archimbaud E, Rowlings PA, et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukemia. Ann Intern Med. 1996;124:311\u2013315.","DOI":"10.7326\/0003-4819-124-3-199602010-00005"},{"key":"2019111702061315000_R11","doi-asserted-by":"crossref","unstructured":"Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol. 2005;23:5788\u20135794.","DOI":"10.1200\/JCO.2005.03.962"},{"key":"2019111702061315000_R12","doi-asserted-by":"crossref","unstructured":"Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of Unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3433\u20133438.","DOI":"10.1200\/JCO.2005.04.531"},{"key":"2019111702061315000_R13","doi-asserted-by":"crossref","unstructured":"Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747\u20132753.","DOI":"10.1200\/JCO.2003.12.011"},{"key":"2019111702061315000_R14","doi-asserted-by":"crossref","unstructured":"Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19:1029\u20131033.","DOI":"10.1038\/sj.leu.2403745"},{"key":"2019111702061315000_R15","doi-asserted-by":"crossref","unstructured":"Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912\u20134920.","DOI":"10.1200\/JCO.2007.15.4757"},{"key":"2019111702061315000_R16","doi-asserted-by":"crossref","unstructured":"Dreger P, Stilgenbauer S, Bo\u0308ttcher S, et al. Prognostic factors for outcome of nonmyeloablative allogeneic stem cell transplantation (NST) in poor-risk chronic lymphocytic leukemia (CLL): final results from a prospective multicenter trial (GCLLSG CLL3X study) [abstract]. Blood. 2008;112:212.","DOI":"10.1182\/blood.V112.11.565.565"},{"key":"2019111702061315000_R17","doi-asserted-by":"crossref","unstructured":"Toze CL, Galal A, Barnett MJ, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant. 2005;36:825\u2013830.","DOI":"10.1038\/sj.bmt.1705130"},{"key":"2019111702061315000_R18","doi-asserted-by":"crossref","unstructured":"Farina L, Carniti C, Dodero A, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica. 2009;94:654\u2013662.","DOI":"10.3324\/haematol.2008.000273"},{"key":"2019111702061315000_R19","doi-asserted-by":"crossref","unstructured":"Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood. 2005;.106:4389\u20134396.","DOI":"10.1182\/blood-2005-05-1778"},{"key":"2019111702061315000_R20","doi-asserted-by":"crossref","unstructured":"Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective EBMT analysis. J Clin Oncol. 2008;5094\u20135100.","DOI":"10.1200\/JCO.2008.16.2982"},{"key":"2019111702061315000_R21","doi-asserted-by":"crossref","unstructured":"Ritgen M, Bo\u0308ttcher S, Stilgenbauer S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008;22:1377\u20131386.","DOI":"10.1038\/leu.2008.96"},{"key":"2019111702061315000_R22","doi-asserted-by":"crossref","unstructured":"Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793\u20134807.","DOI":"10.1182\/blood-2008-08-077941"},{"key":"2019111702061315000_R23","doi-asserted-by":"crossref","unstructured":"Moreno C, Villamor N, Esteve J, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107:4563\u20134569.","DOI":"10.1182\/blood-2005-09-3634"},{"key":"2019111702061315000_R24","doi-asserted-by":"crossref","unstructured":"Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006;12:1056\u20131064.","DOI":"10.1016\/j.bbmt.2006.06.004"},{"key":"2019111702061315000_R25","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007;137:355\u2013363.","DOI":"10.1111\/j.1365-2141.2007.06591.x"},{"key":"2019111702061315000_R26","doi-asserted-by":"crossref","unstructured":"Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111:446\u2013452.","DOI":"10.1182\/blood-2007-07-098483"},{"key":"2019111702061315000_R27","doi-asserted-by":"crossref","unstructured":"Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867\u20132873.","DOI":"10.1182\/blood-2006-02-003954"},{"key":"2019111702061315000_R28","doi-asserted-by":"crossref","unstructured":"Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12\u201317.","DOI":"10.1038\/sj.leu.2404441"},{"key":"2019111702061315000_R29","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Zenz T, Winkler D, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial [abstract]. Blood. 2008;112:290.","DOI":"10.1182\/blood.V112.11.781.781"},{"key":"2019111702061315000_R30","doi-asserted-by":"crossref","unstructured":"Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322\u20133329.","DOI":"10.1182\/blood-2008-04-154070"},{"key":"2019111702061315000_R31","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I\u2013II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26:196\u2013203.","DOI":"10.1200\/JCO.2007.11.8513"},{"key":"2019111702061315000_R32","doi-asserted-by":"crossref","unstructured":"Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II Trial of the German CLL Study Group (GCLLSG) [abstract]. Blood. 2008;112:330.","DOI":"10.1182\/blood.V112.11.330.330"},{"key":"2019111702061315000_R33","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation-specific comorbidity index (HCT-CI): a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20132919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"2019111702061315000_R34","unstructured":"Dreger P. Chronic lymphocytic leukemia: the role of stem cell transplantation. Hematology Education: the education programme for the annual congress of the EHA. 2008;2:314\u2013319."},{"key":"2019111702061315000_R35","doi-asserted-by":"crossref","unstructured":"Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8\/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009;27:1644\u20131652.","DOI":"10.1200\/JCO.2008.18.7740"},{"key":"2019111702061315000_R36","doi-asserted-by":"crossref","unstructured":"Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood. 2006;107:1724\u20131730.","DOI":"10.1182\/blood-2005-08-3372"},{"key":"2019111702061315000_R37","unstructured":"Schetelig J, Milligan D, Niederwieser D, et al. In-vivo T-cell depletion in allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: a retrospective EBMT analysis [abstract]. Bone Marrow Transplant. 2009;43:S259\u2013S260."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/602\/645553\/602_609ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/602\/645553\/602_609ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T06:22:06Z","timestamp":1590301326000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/602\/19855\/Allotransplantation-for-chronic-lymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.602","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}